BALTIMORE, Jan. 15, 2019 /PRNewswire/ -- Popper and Co., a strategy consulting and transaction advisory firm guiding medical technology and life sciences companies working on the leading-edge of diagnostics and patient management, announced today the addition of Vincent Linder, PhD and Gene Vivino to its growing team of industry and clinical senior advisors. Both Dr. Linder and Mr. Vivino provide strong industry knowledge and extensive operating experience, in addition to broad networks in both Europe and Asia.
"At Popper and Company, we believe that diagnostics information will be increasingly necessary to drive more effective and efficient healthcare," said Popper and Company Co-founder and President Caroline Popper MD, MPH. "We have a strong team of experts who have both experienced the power of diagnostics information, and who envisage this information-rich healthcare future, to foster the businesses that will implement real change in the industry. To that end, we are delighted that Gene and Vincent will join us in leading this charge and expanding our global reach."
Dr. Linder is based in Portugal and has shepherded microfluidic technology out of academia, through product development and U.S. Food and Drug Administration (FDA) approval, and into commercialization. Dr. Linder also co-founded Claros Diagnostics, a technology company spun out of Harvard University. At OPKO Health, he was responsible for the technical and regulatory oversight for the launch of 4Kscore®, a blood test used in the management of prostate cancer. He is named on more than 300 issued patents in microfluidics and point-of-care diagnostics.
Mr. Vivino has held leadership positions in business development and strategy and has extensive experience in emerging markets, particularly China and Greater Asia. He was formerly Becton Dickinson's Vice President of Strategic Planning for Greater Asia and has spent three decades planning, building and managing technology businesses around the world. Mr. Vivino was the architect of Becton Dickinson's long-term strategic plan for China, creating a key growth driver for the company.
"We understand the importance of offering our clients guidance and recommendations that are actionable and that precisely address their most important challenges," said Popper and Company Co-Founder Ken Walz. "Adding Gene and Vincent, and their functional experience and understanding of European and Asian markets, further enhances the ways that we can assist our existing and new clients. As importantly, both share our firm's passion for commercializing technologies that use information to improve efficiency in healthcare."
About Popper and Company
Popper and Company guides companies working on the leading edge of diagnostics and patient management, and who recognize the value of applying information-generating technologies to the challenges of biology and medicine. We provide our clients with insights that drive product development decisions, with the tools necessary to articulate the value their products create, and with the tactics to drive market adoption. The Popper and Company team has deep expertise, world-class analytical capability, road-tested knowledge and a robust understanding of the opportunities and risks across multiple markets and geographies. We provide strategic insights that chart a clear path forward for our clients—assisting them in gaining a competitive edge by transforming information and analysis into informed business decisions. For more information, visit popperandco.com.
SOURCE Popper and Co.